Investigation of differentially expressed microRNAs in chicken chorioallantoic membrane during influenza A infection by Chini, Sinduri
INVESTIGATION OF 
DIFFERENTIALLY EXPRESSED 
MICRORNAS IN CHICKEN 
CHORIOALLANTOIC MEMBRANE 
































It has been rightly said by E. D. Kilbourne, “If influenza is a riddle wrapped in mystery inside 
an enigma, then the viral genes are the riddle, the variable surface antigens for which the code 
are the mystery, and the course and cause of epidemics the ultimate enigma.” 
Influenza is a serious global issue that has a significant impact worldwide. It has the potential 
to cause and has caused annual outbreaks as well as sporadic pandemics in the past, which is 
of global health concern. Because of its unique properties of antigenic shift and drift, influenza 
viruses can evade immunity. There is a need for developing rapid, highly sensitive and specific 
diagnostic tests for influenza infection detection and vaccines for better immunisation. A 
universal influenza vaccine has still not been designed which can create a long-lasting 
immunity in the host. The current egg-based vaccines have many disadvantages including the 
anticipation of egg demand at large-scale, allergies and productivity. On top of it, the complex 
and time-consumptive process for seasonal vaccines manufacture makes it difficult for every 
individual to receive the vaccine on time before the onset of influenza season.  
With the discovery of microRNAs and their role in post transcriptional gene regulation, a new 
era involving microRNAs is being explored for diagnosis, vaccine production and much more. 
MiRNAs are short, endogenous class of RNA which are ~19-23 base pairs long. The work on 
this project involves the investigation of differentially expressed miRNAs in embryonated 
chicken eggs. There are several changes taking place in the egg which may either be stimulating 
or inhibiting the viral replication. This study will search for distinct miRNAs which are directly 
or indirectly affecting the hosts’ immunity and thus, studying the relationship between host 
miRNAs and influenza virus repertoire. This might help in future studies to explore methods 
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1. Introduction to influenza 
 
Influenza is the paradigm of a viral disease and influenza viruses are the most common causes 
of human respiratory infections. It is among the most significant because they are responsible 
for causing high morbidity and mortality. It is estimated that seasonal influenza affects 5 to 
15% of the population annually, resulting in anywhere between 250,000 and 500,000 deaths 
globally (WHO Seasonal Influenza). Influenza has been estimated to be associated with 366 
respiratory and 1,400 all-cause deaths, 218,000 hospitalisations and over 300,000 general 
practice consultations per annum in Australia (Muscatello et al., 2014, Newall, 2007). 
 
1.1 Influenza as a disease 
Influenza is an acute respiratory disease, which is characterised by the sudden onset of high 
fever, cough, headache, malaise and inflammation of the upper respiratory tract. Acute 
symptoms often persist for 7-10 days. Weakness and fatigue remain for weeks. The infection 
can manifest in a variety of ways, from mild to severe illness or even leading to death. People 
of all ages are beset, but it is highly prevalent among school-age children. The most vulnerable 
to this disease are the individuals in the extreme of the age spectrum with disease severity being 
highest in infants, the elderly and those with latent illnesses or comorbidities (Centres for 
Disease, 2000). People suffering with chronic pulmonary or cardiac disease, or diabetes 
mellitus, are at high risk of developing complications associated with influenza (Glezen et al., 
2000). This includes haemorrhagic bronchitis, pneumonia, and death. Replication of influenza 
A virus is at peak within 48 hours after inoculation onto the nasopharynx and declines slowly 
after 6 days.  
 
1.2 The global disease burdens 
The viruses have been known to cause annual winter outbreaks and occasional pandemics of 
disease in humans. There have been several influenza A virus pandemics since 1700 such as 
1918 Spanish flu, 1957 Asian flu and 1968 Hong Kong flu (Subbarao and Joseph, 2007b). The 
worst pandemic occurred in 1918, Spanish influenza as it is popularly known as (Johnson and 
Mueller, 2002), which killed 50 million people worldwide (WHO Global Influenza Program, 
2009). Influenza B viruses can cause periodic epidemics but not pandemics while influenza C 
viruses are endemic and occasionally cause mild respiratory disease (Taubenberger et al., 
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2008). Influenza is associated with both direct and indirect costs through health care costs and 
productivity losses, thus affecting at the economical level (Kate Pennington, 2016). 
Fig 1.1 illustrates the percentage of respiratory specimens that tested positive for influenza 
subtypes across the globe as on 2nd March 2018. This is the usual trend for the seasonal 
influenza to occur. During September to February, the winter tend to peak in the northern 
hemisphere and other parts of the world except the Australasia. It is in this period the incidence 
of influenza infection also maximises (Reichelderfer et al., 1989). Influenza A (H1N1) is the 
most widespread type of infection in comparison to the other subtypes of influenza. In Australia 
and New Zealand, approximately 11-20% of respiratory specimens were influenza positive. 
Among these, influenza A (H3) was the most common form of infection which is followed by 
influenza B and influenza A (H1N1) infections.  
In fig 1.2, the occurrence of respiratory specimens that were influenza subtypes positive were 
more prominent in Australia and New Zealand and the other neighbouring countries. This 
figure represents the percentage of influenza subtypes positive specimens across the globe as 
on 12th October 2018. Winter is at peak in these countries from June to August (Reichelderfer 
et al., 1989, Meteorology) so, the incidence of influenza infection rose to 21-30%. Influenza A 
(H1N1) pdm D9 strain was majorly observed in this period. This was followed by the presence 
of influenza A (H3) strain, influenza A (not subtyped) and B strains. 
Fig 1.3 exemplifies the number of specimens which were tested positive for influenza by 
subtype in the period from July 2017 to Oct 2018.  It can be observed that there was a spike in 
the number of influenza positive tested specimens from July 2017 to Oct 2017. A greater 
portion of these specimens comprised of influenza A (not subtyped), followed by influenza B 
(lineage undetermined). Along with these, there was a surge in the number of influenza A (H3) 
during the same time. Furthermore, during the winter of 2018 the number of cases of influenza 
A (H1N1) pdm09 had increased. Side-by-side, the occurrence of influenza A (not subtyped) 
increased with the presence of influenza B (lineage undetermined) in the influenza positive 
specimens. 
The rise in incidences of influenza positive specimens and the inefficiency of the current 
prophylactic measures to tackle with the changing strains of influenza virus has already raised 





Fig 1. 1 Percentage of respiratory specimens that tested positive for influenza and 
distribution of influenza subtypes as on 2nd March 2018 (GISRS  2018a). Reproduced 





Fig 1. 2 Percentage of respiratory specimens that tested positive for influenza and 
distribution of influenza subtypes as on  12th  October 2018 (GISRS  2018a). Reproduced 
this image with their permission. 
 
 
Fig 1. 3 Number of specimens positive for influenza subtypes in Australia (GISRS  
2018b). Reproduced this image with their permission. 
 
1.2.1 How do the vaccines work? 
Vaccines are used for immunisation purposes wherein antibody as well cell-mediated immunity 
play a role against invading influenza viruses. The immune system recognises viral molecules 
including both proteins and nucleic acids, by initiating an immune response. This includes an 
innate immune response as well as an adaptive immune response. The innate immune response 
is very fast, but has no memory, so it doesn’t give any lasting protection. The adaptive response 
does have a memory – this protects us from future exposure to the same virus. The adaptive 
immune response is mediated by lymphocytes (B and T cells). B cells produce antibodies 
against viral proteins, while cytotoxic T cells can kill infected cells. Dead virus is not very good 
at activating cytotoxic T cells, so we rely more on the antibody response to give us protection. 
Antibody mediated immunity works by either blocking HA attachment, inhibiting NA activity 
or inhibiting M2 ion channels (Thomas et al., 2006). Cell-mediated immunity works by 
recognising antigenic peptides and engaging cytotoxic cells to kill infected cells. Only 
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antibodies against HA can be used for immunisation purposes as the other processes occur only 
after infection. Thus, this is the underlying principle of the development of influenza vaccines 
(Subbarao et al., 2007).   
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Fig 1. 4 Various adaptive immune responses against influenza virus. A depicts antibodies against 
HA protein blocking either the attachment of the virus to the host cell receptor or block the fusion of 
virus and host membrane. These are the antibodies which are involved in vaccine protection against 
influenza infection. B represents the antibodies generated against NA protein, which restrict the 
release of virus from infected cells, have been linked with the reduction of severity of the infection. C 
highlights the antibodies produced against M2 protein that intervenes the virus assembly or constrain 
proton transport. D shows responses of CD8+ t-cells that has been correlated with the clearance of 




1.2.2 About influenza virus 
Influenza viruses belong to the Orthomyxoviridae family. Influenza A and B viruses belong to 
one genus and influenza C viruses belong to another genus (Neumann, 2009). 
1.2.2.1 Viral structure 
Influenza A virus is subdivided by antigenic characterization of hemagglutinin (HA) and 
neuraminidase (NA) surface glycoproteins that project from the virion. There are 18 HA and 
11 NA subtypes known (Petrova and Russell, 2018). The nomenclature of influenza viruses 
are as follows according to World Health Organisation- first the type of virus is designated (A, 
B or C), then the host, place of isolation, isolation number and year of isolation, separated by 
slashes, for example:  A/duck/England/1/1956.  
Influenza A and B viruses have indistinguishable structure (fig 1.5). They are spherical or 
filamentous in shape. The influenza A virion is covered with glycoprotein spikes HA and NA. 
A small number of matrix (M2) ion channels traverse the lipid envelope (Palese, 2007). The 
matrix M1 is overlaid by the envelope and HA, NA and M2. Hemagglutinin is a highly 
antigenic membrane glycoprotein, facilitates virion entry into the human epithelial cells by the 
α-2,6 galactose linkages present in the sialic acid receptors. Neuraminidase enzyme prevents 
aggregation of virions within the host cell and also aids in cell-to-cell spread by cleaving 
glycosidic linkages to sialic acid. The inability of cross-reactivity of the antibodies with the 
corresponding antigenic proteins of virions A and B differentiates the 2 viral subtypes.  
 
The total size of influenza genome is 13.5 kbp. The genome of influenza A and B viruses 
consists of eight segments whereas that of influenza C virus consists of seven segments of 
negative sense, single stranded RNA. To be able to cause an infection, a single virus particle 
should contain eight (or seven) RNA segments. The eight RNA segments encode 10 gene 
products. These are PB1, PB2, PA polymerases, HA, NP, NA, M1, M2 proteins, NS1 and NS2 








Fig 1. 5 Structure of influenza virus (Bouvier, 2008). HA stands for hemagglutinin, NA 
for neuraminidase, M1 & M2 are matrix protein 1 & 2, NS1 & NS2 are non-structural 
protein 1 & 2, NP is nucleoprotein, PB is polymeric basic and PA is polymeric acidic 
polymerases. 
 
1.2.2.2 Natural hosts of the virus 
This disease has been known to be a zoonosis of swine, birds, horses, and humans. Influenza 
probably existed among mammals and birds in antiquity initially. But, as animals started being 
domesticated and human populations became concentrated, the transfer of influenza from 
zoonotic to human realm became obvious.  Influenza virus can maintain itself in less 
concentrated populations because of the short-lived nature of the immunity of hosts owing to 
antigenic drift and shift of the virus. Because of the ephemeral nature of the immunity influenza 
confers to a host, it affects people of all ages (Aufderheide et al., 1998, Schell et al., 1994, 
Hayden and Palsese, 2002, Shortridge, 1992). 
Type B and C influenza viruses are isolated from humans, but influenza B virus has also been 
isolated from seals and the later type from pigs and dogs. Influenza A viruses infect a wide 
variety of warm-blooded animals which includes birds, pigs, horses, humans and other 
mammals. The natural reservoir of all known subtypes of influenza A virus are aquatic birds 
(see fig 1.6). These are also the ultimate source of human pandemic influenza strains. In short 
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humans are affected by influenza A, B and C viruses (Taubenberger et al., 2001;Taubenberger 
et al., 2008;Webster et al., 1992). 
Fig 1. 6  Cross-species transmission of influenza A virus. Red and blue represents group 1 
HA and group 2 HA subtypes respectively (Yoon et al., 2014). 
1.2.2.3 Evolution of the virus 
The epidemiological behaviour of influenza virions is dependent on 2 types of antigenic 
variation in HA and NA molecules. These variations are antigenic drift and shift. The antigenic 
shift is observed because of the segmented genome of the virus. Segmental re-assortment in 
the genome occurs between HA segment and/or NA segment between subtypes of influenza 
viruses (Desselberger et al., 1978), thus resulting into completely novel antigenic proteins, to 
which the human community has no pre-existing immunity. Pandemic influenza occurs due to 
this wherein humans are immunologically naïve to it. This is antigenic shift. These viruses 
accumulate point mutations during replication because of the lack of proof-reading activity of 
the RNA polymerase complex. Their genes have high mutation rates. These mutations change 
amino acids in the antigenic part of HA and NA that produce selective advantages for viruses 
to evade the existing immunity. These substitutions are more commonly observed in the 
10 
 
antigenic regions (A-E) on the globular domain of HA1 which are essential for binding with 
the virus-neutralizing antibodies (Caton et al., 1982). This is antigenic drift. Thus, the viruses 
can evade the previously acquired immunity by either antigenic drift or antigenic shift. The 
rate of drift varies among different genes and virus types. According to the epidemiological 
studies done in humans, only influenza A viruses are amenable to antigenic shift. Until now, 
16 antigenically HA subtypes and 9 NA subtypes of influenza A viruses are known to circulate 
in their natural hosts which rarely cause any symptomatic disease in them but under conducive 
situations might transmit to other species and cause a wide range of morbidity and mortality 
(Yoon et al., 2014).  Fig 1.7 illustrates the emergence of three pandemics of 20th century. After 
the Spanish flu pandemic, the influenza A H1N1 virus took to re-assortment of genes from 
avian flu virus and led to the evolution of influenza A H2N2 virus, which caused another 
pandemic. Again, this new subtype of virus reasserted its genes from avian flu virus and 
evolved to influenza A H3N2 virus. With every emergence of a new subtype of influenza virus, 
a pandemic occurred claiming thousands of lives worldwide (Elderfield and Barclay, 2011, 
Cox et al., 2005). 
 
Fig 1. 7 The timeline representing the emergence of three pandemics of the 20th century 
(Elderfield et al., 2011). Re-assortment of genes from the causal influenza virus responsible 






Fig 1. 8 Phylogenetic relationship of different influenza A virus strains evolved since it’s 




It is not possible to predict which subtype of influenza virus might cause a pandemic, thus an 
ideal vaccine should elicit an immune response that protects the host from a wide range of 
influenza viruses. For this, universal vaccines are being designed which will cover a broad 
spectrum of influenza viruses. At the moment, seasonal influenza vaccines are used which work 
against influenza A H1N1 and H3N2 and influenza B viruses. These need to be updated every 
1 to 3 years because of the antigenic shift and antigenic drift occurring in these viruses.  
Inactivated virus vaccines, sub-unit vaccines and live-attenuated virus vaccines are being 
developed for pandemic influenza. The major licensed or late stage influenza vaccines have 
been enlisted in table 1.2. Inactivated virus vaccines made with subtype H5 and H9 have been 
shown to be effective in preclinical trials. The viruses used here have recombinant HA 
glycoprotein which have altered immunogenicity. For live attenuated vaccine, strains are 
generated by the re-assortment of wild type influenza virus having HA and NA genes of interest 
with cold adapted donor AA (H2N2) influenza virus. This virus has 5 mutations in 3 gene 
segments that contributes to its high degree of phenotypic and genotypic stability (Subbarao 
and Joseph, 2007a). 
1.2.3 The process of vaccine production  
In a situation of an epidemic/pandemic, an exaggerated process has been chalked out which 
take months to prepare the final product. Fig.1.9 represents the vaccine production process in 
response to a new pandemic. The World Health organisation (WHO) conducts a surveillance 
worldwide to monitor the epidemiology of influenza viruses. This system performs the detailed 
analysis of influenza viruses that have been isolated from humans as well as from animals and 
thus, works for the detection of newly evolved antigenic variants of the influenza A (H1N1 and 
H3N2) and B strain viruses to which humans are likely to be susceptible. 
The surveillance data are reviewed twice yearly by WHO Collaborating Centre investigators.  
It has been pointed by these epidemiological data that in temperate climates, influenza viruses 
circulate primarily during winter months. Hence, in Northern hemisphere and Southern 
hemisphere, the viruses are reviewed for antigenic variants causing human disease, in February 
and September respectively. The variants that must be included in next season’s influenza 
vaccine is decided on the basis of these reviews. An accurate cross match between vaccine 
composition and circulating strains is anticipated by them. It is after this stage that the vaccine 
companies have approximately 6 months to produce their vaccines and deliver them to the 
health care providers.   
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Once the viral strains have been determined, candidate high-growth seed strains must be 
prepared by WHO Collaborating Centres, which are further tested by the manufacturers and 
put into production. There are several factors which affect the vaccine production timetable. 
Firstly, there are 2 production cycles of vaccine per year for the manufacturers to undertake, 
one each for Northern and Southern hemisphere. Next, the duration within which the delivery 
of vaccines is to be made is crucial as annual vaccination programs are conducted during the 
few months just before the expected circulatory period of flu viruses.  The final factor that 
dictates the timetable is the availability of embryonated eggs. As the vaccines are produced in 
embryonated eggs, the number of eggs required to produce required number of doses of 
vaccines that is expected by the market, needs to be anticipated well in advance of beginning 
of production. 
 
Fig 1. 9 Pandemic influenza virus vaccine production timetable. This figure depicts the vaccine production 
process on the onset of a new pandemic. Orange stars represent steps that can be accelerated by using novel 
technologies such as gene synthesis or reverse genetics can be used for seed strain preparation and verification. 
After the seed strains are prepared, viruses can be included in a backbone that has been optimised for growth on 
a selected substrate which will save time for growth optimisation (WHO, 2009) 
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All influenza vaccines are currently produced in embryonated chicken eggs. The present 
inactivated influenza vaccine is the bacterial endotoxin-free trivalent influenza vaccines (TIV) 
which is prepared with 15 µg HA from each of virus A/H1N1, A/H3N2 and B. The 
conventional vaccine manufacturing protocol is illustrated in fig.1.10. Firstly, the simultaneous 
infection of allantoic sac of the chicken embryo with high growth phenotype of H1N1 
(A/PR/8/34) which is laboratory-grown, and the epidemic strain is done to prepare the seed 
strain. The resultant high-growth reassortants are selected which doesn’t have PR8 or PR8-like 
surface glycoproteins encoding genes. Large-scale production of selected seed strain 
containing HA and NA of epidemic strain is carried out in fresh eggs to obtain sufficient doses 
of vaccine virus. The vaccine viruses are then purified and inactivated by chemical treatments 
(Bardiya and Bae, 2005). 





1.2.4 Limitation of current vaccines 
 
There are many hurdles for the successful vaccinisation of a majority of the population against 
pandemic (seasonal) influenza. The problems are at each level- from production to distribution 
and further to immunisation. In the level of production, egg-based production of vaccines is 
considered to be inefficient because of its complex procedure, labour-intensive work, low HA 
protein yield per titre, weak immunogenicity, prone to antigenic changes during passaging and 
the strain H5N1 being toxic to the embryo (Bardiya and Bae, 2005). In addition to this, the 
supply of eggs for this must be anticipated and planned well in advance to produce required 
doses of pandemic flu.  
Another prime problem is the gap between demand and supply for the pandemic flu vaccines. 
The current seasonal vaccine is a trivalent influenza vaccine that contains 15 µg of HA antigen 
for each of 3 virus strains with a total of 45 µg of HA (Bridges et al., 2003, Fedson, 2003). In 
2006, the global annual capacity for the seasonal egg-based vaccine production was estimated 
to be 1 billion doses of monovalent vaccines which is equivalent to >300 million doses of a 
seasonal trivalent vaccine inclusive of a 3-month window period for the manufacturing to 
begin. Considering that a single dose of 15 µg of HA constitute a monovalent vaccine, this 
would cover about 40% of the world’s population in 2 years and would further take an 
estimated time of about 5 years, with >2 billion eggs to produce enough quantities of vaccine 
to cover the entire population (1 egg yield ~3 monovalent doses). If this goal needs to be 
achieved within a year, then the capacity of the vaccine manufacturing industries has to be 
scaled up a factor of 6. With an ever blooming population and its demands, it is difficult to 
catch up with the supply and distribution (Ulmer et al., 2006). The reasons for the shortage of 
supply are lack of manufacturing infrastructure and egg availability. The reason for low 
investment in new production technologies is due to the low profit margin that is gained from 
the influenza vaccine production. Therefore, most of the companies are not interested in huge 
investments in this manufacturing sector.  
The time-consuming pandemic vaccine production doesn’t allow for any slack in the system 
for distribution lead time buffering nor does it allow for staggered production. Also, there have 
been issues with low immunisation rates owing to the perception of side effects and fear of 
needle injections. Invention of non-invasive methods for flu vaccination might increase the 
demand for vaccines which would in turn increase the profit margins and hence, will attract 




1.2.5 Chorioallantoic Membrane 
 
The chorioallantoic membrane (CAM, see fig 1.11) is the outermost extraembryonic vascular 
membrane found in the embryonated eggs of some amniotes such as birds and reptiles. It is the 
product of fusion of splanchnic mesoderm of the allantois and the somatic mesoderm of the 
chorion (Gilbert, 2003). In mammals, it forms a part of placenta (Ferner et al., 2011). By day 
12 of incubation, the CAM develops and covers the whole surface of the inner shell membrane 
of the chicken. This extraembryonic membrane is the sole source of support for physiological 
requisites of embryo which includes gaseous exchange, nourishment and excretion in absence 
of maternal participation during development. This also plays an important role in osteogenesis 
(Coleman et al., 1970). 
Fig 1. 11 Structure of CAM and various techniques for inoculation (Vincent Racaniello 
and Rey, 2009) 
As mentioned before, the production of flu vaccines is centred around embryonated chicken 
eggs. The common used method of inoculation is chorioallantoic membrane inoculation. At 
approximately 10-11 days of embryonic development, the viral inoculum is injected into the 
allantoic fluid of the egg which is then allowed to incubate for 24-72 hours (Brauer and Chen, 
2015). The multiplied viruses are released in the allantoic fluid which can be checked by 
examining the allantoic fluid for an increase in the viral titre (Hoyle and Infection, 1950, Hoyle 
and Infection, 1954, Fulton and Isaacs, 1953). The viral titre can differ depending on the strain 
of virus used.  
It was predicted decades ago that CAM would be an important site of influenza replication 
(Burnet, 1941). It was, however, recently recognised for its key role in vaccine production 
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which has prompted further investigation (McDonald, 2017). Several changes occur in CAM 
during this process including the molecular changes (Widjaja et al., 2006, Edinger et al., 2014). 
A cascade of reactions starts from the initial point of viral entry till the release of new viruses 
in the allantoic fluid and further ahead. The studies of changes in the mRNA pool of CAM is 
being studied but the aspect of miRNA regulation hasn’t been explored yet. This constitutes 
the main theme of my project which will be studying the differently regulated miRNAs in 
H1N1 and H3N2 infection in CAM of chick eggs. 
 
1.3 MicroRNA 
MicroRNAs (miRNAs) are single-stranded RNAs of approximately 19-23 nucleotides in 
length. These are endogenous, non-coding and represent a novel class of gene regulators of 
mRNA degradation (Jonas and Izaurralde, 2015). The small RNAs regulated gene expression 
occurs by 3 mechanisms- RNA cleavage (Bartel, 2004), transcriptional silencing and 
translational repression (Zhang et al., 2006). They sometimes also modulate the up-regulation 
of translation (Vasudevan et al., 2007).   
In 1993, the first miRNA was discovered during the studies of timing of embryonic 
development of different larval stages of the nematode C. elegans (Lee et al., 1993). These are 
involved in various biological activities such as development, differentiation, growth and 
metabolism (Guo et al., 2005, Hatfield et al., 2005, Lee et al., 1993, Lindsay, 2008). In recent 
studies in mammals, these have been reported to participate in the regulation of immunity as 
well (Lindsay, 2008). It has been proved that one miRNA can control the expression of more 
than one target mRNAs and one mRNA’s expression can be controlled by more than one 
miRNA. The interaction between miRNA and mRNA are usually restricted to a seed region 
which is a stretch of consecutive ~6 to 8 sequence and is highly conserved among species. This 
is present in the 5’terminus of the miRNA strand that is also known to contribute more to the 
specificity and activity in binding targets. Any change in this seed region changes the target 




To ensure uniformity and ease of cataloguing miRNAs, a uniform system of annotation and 
nomenclature has been adopted (Ambros, 2003, Griffiths-Jones et al., 2006). These are 
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numbered sequentially on the order of their discovery. Those which have been confirmed 
experimentally are assigned a number that is prefixed with “miR” followed by a dash. For 
identifying which organism the miRNA is from, miR is prefixed with 3 letters denoting the 
organism’s scientific name. the mature miRNA is represented with miR (capitalised R) and the 
uncapitalized r refers to both the miRNA gene and the predicted stem-loop component of the 
primary transcript i.e. precursor miRNA. Earlier the miRNA genes were named after their 
phenotypes such as lin-4, let-7, etc.  
Mature miRNAs that have identical sequences and originate from discrete precursor sequences 
and genomic loci contain numeric suffix in their identifiers (for example, hsa-miR-219-1 and 
hsa-miR-219-2). Besides this, miRNAs with 1 or 2 nucleotides difference in their mature 
sequences are denoted with a lettered suffix such as hsa-miR-130a and hsa-miR-130b. These 
are also known as miRNA sisters. IsomiRs are mature miRNAs that are generated from one 
pre-miRNAs when subjected to a variety of modifications such as trimming at 5’or 3’ends, 
substitutions, insertions, deletions or addition at 3’end (Morin et al., 2008). These vary in length 
or sequences. Each miRNA gene locus can potentially produce two mature miRNAs- one each 
from 5’and 3’strands of the precursor. This is true for many miRNAs, however it is also quite 
common for only a single miRNA to be expressed, while the other gets degraded during 
biogenesis. If the 2 strands are both expressed, then the one which is more prevalent and is 
predominately expressed is designated as the ‘mature strand’ (sometimes known as guide 
strand). This is guide strand is more biologically active as compared to the other ‘passenger’ 
strand which is designated as the ‘star’strand (miRNA*). However, when the strands can’t be 
defined as the predominant one, the miRNA identifier includes either a 5p or 3p suffix (miR-
125a-5p or miR-125a-3p). More recently, we are shifting to the 5p/3p nomenclature for all 
miRNAs and slowly moving away from the mature/star naming convention. This is because it 
is now recognised that deciding which one is the mature and which one is the star depends on 




miRNA biogenesis is a multistep process (fig 1.12). In the nucleus, RNA polymerase II 
transcribes the miRNA gene (Lee et al., 2004) to produce primary miRNA (pri-miRNA) 
hairpin. This is processed into precursor miRNA (pre-miRNA) by Microprocessor complex 
comprising of RNA polymerase III Drosha (Lee et al., 2003) and Di-George syndrome critical 
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region 8 (DGCR8) protein (Gregory et al., 2004). The enzyme Drosha recognises the ds RNA-
ss RNA junction at the base of hairpin and 2 DGCR8 proteins ensure correct cleavage by 
binding to the stem (Kwon et al., 2016). IsomiRs are produced by the alternative cleavage by 
Drosha. Pre-miRNAs are called ‘hairpins’ because of their shape and have ~70 nucleotides. 
The hairpin end has a 2-nucleotide overhang at 3’end along with a hydroxyl and a 5’phosphate 
(Nicholson, 2014). Exportin 5 protein recognises this overhang followed by transporting the 
pre-miRNA to the cytoplasm (Okada et al., 2009). The RNase III enzyme Dicer in the 
cytoplasm, binds the pre-miRNA by identifying the 5’phosphate, loop structure and 
3’overhang. This molecular ruler cleaves pre-miRNAs at a species-specific length and 
produces a mature miRNA duplex with another distinct 2-nucleotide 3’ overhang (MacRae et 
al., 2007). The guide strand is loaded into Argonaute (AGO) while the passenger strand is 
sometimes degraded  or sometimes expressed (Rand et al., 2005).     
 Fig 1. 12 The endogenous pathway of miRNA biogenesis (Samir et al., 2016) 
 
1.3.3 Techniques for the study of miRNA 
Since the discovery of miRNAs, studies have been performed to understand the role of 
miRNAs in a wide variety of biological processes and diseases. A common aspect to many of 
these studies is miRNA expression profiling. Commonly used approaches include Northern 
blotting, microarrays and reverse transcription quantitative real-time PCR (qRT-PCR). More 
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recently, Next Generation Sequencing (NGS) has proven itself to be a powerful high 
throughput technique for quantifying miRNAs. 
NGS has helped a lot in profiling miRNAs where the generated reads were mapped to the 
reference genome of the concerned species. NGS offers to explore all expressed miRNAs in a 
condition, giving the possibility to comprehensively define signatures at the basis of the 
regulatory circuits that control many pathways, in this case in influenza infected CAM of 
embryonated chicken eggs. The advancement in NGS technologies allows an unprecedented 
scale and depth in miRNA profiling. They also have the potential to discover novel miRNAs 
(Lee et al., 2010, Gallo et al., 2018).  
Based on miRNA-target interactions, several computational approaches have been developed. 
Most of these scan for potential target sequences of miRNAs in the 3’untranslated regions 
(UTRs). This is based on homology and structural criteria such as sequence complementarity, 
stability of the RNA-RNA duplex, target-site conservation across species and the presence of 
multiple target sites in the same gene (Bentwich, 2005). One of the target prediction program 
which was used in this study was miRanda (John et al., 2004, Riffo-Campos et al., 2016). It 
predicts targets based on sequence similarity, emphasising on higher matches at the 5’end of 
the mature miRNA. It also takes into account the free energy (ΔG) of the RNA-RNA duplex 
and the extent of the conservation of the miRNA target across relative genomes (Wuchty et al., 
1999). 
There are several miRNA quantitation methods available in the market. Real-time quantitative 
PCR (RT-qPCR) has superior sensitivity and enables specific and sensitive PCR-based 
quantification of miRNAs. This selectively targets mature miRNAs and can easily yield a range 
of linear quantification of 7 log10 units. This is a highly reliable method of detecting miRNAs 
with even 1 nucleotide difference (Chen et al., 2005). Stem-loop RT based TaqMan® 
MicroRNA Assays are believed to be the gold standard method. SYBR-based assay is an 
alternative to TaqMan method which includes SYBR Green dye. TaqMan assays are used more 
commonly because they have been validated before. We prefer to use a pre-designed, pre-







This project involves investigation and identification of differentially regulated miRNAs in 
CAM of chicken eggs which is a significant site of viral replication. It has been observed in 
recent studies that several changes take place in egg upon influenza infection which may either 
stimulate or inhibit viral replication. In addition to this, it was also seen that an immune 
response is generated within CAM. This study will give us information about the differentially 
expressed miRNAs during influenza infection which may be associated with hosts’ immunity 
and thus, enlighten the relationship between host miRNAs and influenza infection. The 
information gained by this research may help to reduce the cost and increase the efficiency of 
vaccine production, thereby saving a larger portion of population in less time. 
 
3. Aims and Hypothesis 
 
 
1. AIM: To analyse differentially expressed (DE) miRNAs expressed in H1N1 and H3N2 
influenza virus infected chicken eggs in silico using differential expression of genes (DESeq) 
and target prediction (miRanda) tools 
HYPOTHESIS: It is hypothesised that there will be miRNAs which will be differentially 
expressed in infected CAMs and their probable target genes will be predicted.   
2. AIM: To validate the differentially expressed miRNAs in CAMS and chicken tissues by 
qRT-PCR 
HYPOTHESIS: It is hypothesised that the differentially expressed miRNAs will be validated 
in CAMs as well as different adult chicken tissues. 
3. AIM: To elucidate a correlation between significant miRNAs and influenza viral 
replication in in vitro gain-of-function and loss-of function studies by qRT-PCR. 
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HYPOTHESIS: It is hypothesised that the differentially expressed miRNAs will have a 
significant impact in the presence of agonist and antagonist. Also, the different treatments 







4. Materials and Methods 
 
This research work can be phased into two categories- bench work and bioinformatics. Some 
preparatory works were done by the team at CSIRO-AAHL before I started with my research. 
These are indicated in the relevant section below. 
4.1 Embryonated chicken eggs and viral strains 
Embryonated Hy-line chicken eggs were used for this project which were on their 10th day 
of embryogenesis. These were available onsite of CSIRO-AAHL. The 2 influenza virus strains 
used were- A/California/07/2009 H1N1 and A/Hong Kong/4801/2014 H3N2. These were 
selected for the infection study as these 2 are the common strains which have been most 
profoundly found to be active during recent seasonal epidemics. As discussed before about the 
scenario of influenza epidemic of Australia in 2017, these 2 strains were the major cause of flu 
that year.     
  
4.2 Preparation of samples for NGS  
This was performed by AAHL staff. 15 eggs were grouped into 3 categories- 5 mock, 5 H1N1 
infected and the remaining 5 H3N2 infected. Mock were labelled MIR1, MIR2, MIR3, MIR4 
and MIR5; H1N1 infected as MIR6, MIR7, MIR8, MIR9 and MIR10 whereas H3N2 infected 
as MIR11, MIR12, MIR13, MIR14 and MIR15. MIR refers to miRNA being isolated from 
various CAM samples. The inoculation was done by direct injection in allantoic fluid. The 
mock was inoculated with PBS, the H1N1 infected with H1N1 viral titre and H3N2 infected 
with H3N2 viral titre. These were kept for 24-hour incubation period. QIASeq™ miRNA 
library kit was used for library preparation. 100 ng RNA per sample was used and quality was 
checked using Bioanalyzer small RNA assay. These were sent for NGS.    
4.3 Bioinformatics 
4.3.1 Next Generation Sequencing and raw data processing 
This was also performed by AAHL staff. The samples were sent to Australian Genome 
Research Facility (AGRF) for NGS. Illumina sequencing was done using HiSeq2500 
platform wherein image analysis was performed in real time by the HiSeq Control Software 
(HCS) v2.2.68 and Real Time Analysis (RTA) v1.18.66.3. Illumina bcl2fastq 2.20.0.422 
pipeline was used to generate the sequence data. 100bp single end reads were used. The raw 
data was cleaned (trimmed and filtered) then mapped to the chicken reference miRNA set in 
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miRbase21. The raw data was of Fastqc quality which had adapters attached to it. These were 
trimmed using cutadapt command. Later after trimming, the reads were filtered based on length 
(18-26 nt). Raw read counts were saved in CSV format for downstream analysis. 
4.3.2 Local and Global Alignment 
Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1990) was used to perform local 
alignment. This was performed on Pearcey, which is a CSIRO high-performance computer 
(HPC) cluster, using the tool command line Blast+ v2.9.0. The sequences from viral genome 
were locally aligned against hairpin gga miRNAs (chicken miRNAs). The alignment 
parameters were set as per the following- evalue 0.5, word size 4, penalty 4, reward 5, gap open 










Fig 4. 1 Outline for BLAST procedure 
Clone Manager was used to globally align multiple sequences of viral genome, mature gga 
(Gallus gallus i.e. chicken) miRNAs and hairpin gga miRNAs. Only the top hit in blast report 







Fetch viral genome 
Load blast module 
Fetch hairpin gga miRNAs from miRbase 
Paste the respective sequences and label 
them properly 
Run the alignment for multiple sequences 
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Fig 4. 2 Outline for Clone Manager workflow 
4.3.3 DESeq2 
Differential gene expression analysis was done using DESeq2 v1.14.1 in RStudio. It is a 
method of normalisation of the count data from high throughput sequencing assays. It is based 
on a model using negative binomial distribution (Love et al., 2014). RStudio is an integrated 
environment (IDE) for the R programming language used for statistical computing and 
graphics (Allaire, 2012). 
The count data from NGS was used in DESeq2 and a sample metadata was created to categorise 
the samples in the NGS data. The significant hits were represented in volcano plots using 
RStudio.   
The sample metadata has been illustrated in table 4.1. 
















































Fig 4. 3 Flowchart for DESeq2 
 
4.3.4 Target prediction 
The significant hits that were obtained from DESeq2 were used for target prediction. This was 
conducted using miRanda. This was also performed on Pearcey (section 4.3.2). The targets of 
the respective miRNAs were searched using chicken coding sequences (CDS) and 3’ 









Fig 4. 4 Flowchart for miRanda 
Load data and metadata 
Filter out low expressed miRNAs 
Perform DE testing 
Export normalized counts 
Export significant DE results 
Load miRanda 
Fetch chicken CDS and 3’UTRs 
Discard sequences which aren’t available 
or with no headers 
Apply cut-off. Run miRanda 
Filter output file for hits 
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4.3.5 Target enrichment 
The targets predicted from miRanda are enriched using DAVID Bioinformatics which is an 
online analytic tool (Huang et al., 2009, Huang et al., 2008). The URL for the database is 
https://david.ncifcrf.gov/home.jsp. Using the in-built Functional Annotation tool, the list 
of predicted genes was clustered based on different aspects of annotation. Reference annotation 
was ‘Homo sapiens’ because human is much better annotated than chicken and most genes 













Fig 4. 5 Protocol for target enrichment 
 
4.4 Validation Study 
For the validation studies, the miRNAs obtained from the computational analysis of NGS 
reports were validated experimentally. For this, 2 miRNAs were selected from the 5 miRNAs 
that seemed to be the most promising ones. These were gga-miR-215-5p and gga-miR-429-5p 
that were found to have increased and decreased expression respectively.  
 
DAVID database 
Functional annotation tool 
Select OFFICIAL_GENE_SYMBOL as the identifier 
Paste gene list 
Select ‘Homo sapiens’ as gene list and background  
Select list type as ‘gene list’. Submit 
View the result in Functional Annotation Clustering 
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4.4.2 miRNA extraction from different samples 
Total RNA including miRNA was extracted from different tissue samples using the miRNeasy 
kit from Qiagen. CAM tissues from chicken eggs were preserved in RNAlater and stored in -
80˚C freezer. RNAlater is a stabiliser which prevents unwanted changes in the gene expression 
profile. The tissues from brain, liver, lungs, spleen and serum also had RNAlater and was 
stored in -20˚C as it was immediately used after harvest.  
The various samples used were: 
SET 1- Mock: CAM1, CAM2, CAM3, CAM4, CAM5 
             H1N1 infected: CAM17, CAM18, CAM19, CAM21, CAM25 
             H3N2 infected: CAM32, CAM34, CAM36, CAM38, CAM39 
 
SET 2- Mock: CAM6, CAM7, CAM8, CAM9, CAM10 
             H1N1 infected: CAM16, CAM20, CAM22, CAM23, CAM24 
             H3N2 infected: CAM30, CAM31, CAM33, CAM35, CAM37 
SET 3- 3 biological replicates each of brain, liver, lungs, spleen, serum 
The difference between SET 1 and SET 2 is the level of viral expression. Good levels of 
replicated virus were observed in the former set as compared to the latter as very low viral 
growth was seen. Harvesting of tissues were performed by colleagues at CSIRO-AAHL. The 
tissues in SET 3 were harvested from 4-8 weeks old chicken.  
The RNA extraction of different samples was performed using miRNeasy micro kit (Qiagen, 
Hilden, Germany). Before starting with the procedure, gloves were cleaned with RNaseZap. 
The new bottles of RWT and RPE buffers were suspended into required amount of 96-100% 
ethanol to obtain the working solution. The whole protocol was performed at room temperature, 
except the step involving phase separation.  
The required number of Eppendorf tubes were labelled according to the samples from which 
RNA was to be extracted. In each tube, tissues were placed according to the labels and 700 µL 
of QIAzol lysis reagent was added. To these, approximately 0.1 g of glass beads with 1 mm 
diameter were added and homogenised using TissueLyser for 2 minutes at 30 beats/sec and 
then another minute at the same frequency with resting on ice between the 2 sets. The 
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homogenates rested on the benchtop for 5 minutes at room temperature (RT) (15-25˚C). To 
these, 140 µL of chloroform was added and shaken vigorously for 15 seconds with the lids 
closed. Again, the homogenates were rested at RT for 2-3 minutes. These were centrifuged at 
12,000g for 15 minutes which was pre-cooled at 4˚C. The upper aqueous phases were 
transferred to new collection tubes and to this 1.5 volumes of 100% ethanol was added. These 
were mixed thoroughly by pipetting up and down several times. These were loaded without 
any delay into RNeasy MinElute spin columns in labelled 2 mL collection tubes, 700 µL of 
respective samples were taken. With the lid closed gently, these were centrifuged at ≥8000g 
for 15 seconds at RT and the flow-through was discarded. This step was repeated with the 
remainder of each samples. To wash the columns, 700 µL of RWT buffer was pipetted into the 
RNeasy MinElute spin columns and with the lids closed, were centrifuged at ≥8000g for 15 
seconds at RT. The flow-through was discarded. The columns were washed with 500µL of 
RPE buffer, followed by centrifugation at ≥8000g for 15 seconds at RT with the lids closed.  
After the flow-through was discarded, the columns were washed with 500 µL of freshly 
prepared 80% ethanol (using nuclease free (NF) water) and then centrifuged at ≥8000g for 2 
minutes at RT. The columns were placed onto new collection tubes and centrifuged at high 
speed for 5 minutes with the lids opened. After the membrane was dried, the collection tubes 
were discarded, and the columns were placed onto 1.5 mL new collection tubes. After 14 µL 
was added to the centre of each column membranes, these were centrifuged at full speed for 1 
minute to elute the RNA. These were stored in -80˚C freezer if not used immediately.  
 
4.4.3 Validation of miRNAs using qRT-PCR 
The RNA concentration was measured using ND-1000 Nanodrop Spectrophotometer 
(Nanodrop Technologies Inc.) by measuring the absorbance at 260nm. Prior to complimentary 
DNA (cDNA) strand synthesis, the RNA from different samples (SET 1, 2 and 3) were diluted 
with NF water so that each sample would have a uniform concentration of total RNA. 
Table 4. 2 Illustration of dilution of the samples so that every 2 μL of the sample 
contains 10ng/μL of miRNAs 

















1 CAM1 72.62 2 3.65 20 7.3 5.3 
2 CAM2 52.76 2 2.65 20 5.3 3.3 
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4.4.3.1 cDNA synthesis 
 
The protocol was performed for validating 2 miRNAs- gga-miR-429-5p and gga-miR-215-5p. 
TaqMan® MicroRNA Reverse Transcription kit, Applied Biosystem (catalogue# 4366596) 
was used for cDNA synthesis and TaqMan RT hsa-miR-215-5p (catalogue# 4427975) and gga-
miR-429-5p (catalogue# 4440886) primers were used. Before setting up the reactions for 
reverse transcription and qPCR, the work bench should be made RNA free. Firstly, the RT kit 
components, RT primer and RNA from various samples were thawed on ice. Once, the 
components have thawed, they were given a quick centrifuge and vortexed for resuspension. 
The RT master mix was prepared according to table 4.3 which included dNTPs, RT buffer, 
RNase inhibitor and reverse transcriptase. 7 μL of RT master mix was added in each labelled 
PCR tubes. This was followed by the addition of 3 μL of RT primer in each PCR tubes. As per 
the labelling, 5 μL of RNA samples were added into the corresponding tubes and one tube 
didn’t have any RNA, instead water was added. This acted as a no control. The tubes were 
sealed properly and were mixed by vortexing and were centrifuged to bring the contents in the 
bottom. Before putting the reaction tubes in thermal cycler, they were incubated on ice for 5 
minutes. The parameters were set according to table 4.4 on thermal cycler. After the reaction 
tubes were loaded in T100 thermal cycler (BioRad), the volume was set at 15 μL and then the 
cycler was started.   
 
Table 4. 3 Measurements of the components for a 10 μL reaction 
 
Reagent Per reaction (μL) 
Total (+10%) (μL) 
for 1 reaction 
100mM dNTPs 0.15 0.2 
Multiscribe™ Reverse Transcriptase 1 1.1 
RT Buffer 1.5 1.7 
RNase Inhibitor 0.19 0.2 
NF Water 4.16 4.6 














4.4.3.2 TaqMan quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
The reagents were thawed on ice before use. TaqMan qRT-PCR kit contains TaqMan assay 
(20x) and Fast Universal qPCR master mix, Applied Biosystem (noAmpErase UNG, 
catalogue# 4352042). The TaqMan assay includes one tube containing small RNA-specific RT 
primer and another tube containing a mix of small RNA-specific forward and reverse PCR 
primer and small RNA-specific TaqMan® MGB probe. Once this was done, the reagents were 
pipetted in 2 sterile Eppendorf tubes- one each for miR-215-5p and miR-429-5p except for 
cDNA also considering the no template control. The reaction mixtures were made according 
to table 4.5. 19 μL of the master mix was transferred into each well of 96-well plate as per the 
samples and 1 μL of cDNA corresponding to the sample. The plate was sealed and then 
centrifuged at 3000g for 5 minutes at room temperature using Allegra™ X-12R Centrifuge, 
Beckman Coulter. The plate was loaded onto Step-one Plus™ Real-time PCR system, Applied 
Biosystem and the parameters were set as per table 4.6 and the cycle was thereafter started.  




Total (+10%) (μL) 
for 1 reaction 
TaqMan Assay (20x) 1 1.1 
Fast Universal qPCR 10 11 







(min) Temperature (˚C) 
Hold 30 16 
Hold 30 42 
Hold 5 85 
Hold ∞ 4 
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4.4.4  Data analysis 
The data analysis was done using GraphPad Prism software which calculated the mean and 
standard deviation between the samples and graphs were created showing the error bars. 
Also, the statistical analysis was done using the same software and two-tailed, unpaired t-test 
was performed for the significance of the measurements. The threshold significance was set 
at P < 0.05. 
4.5  Functional Study 
To understand the role and pattern of expression of miR-215-5p, a functional study was done 
which included in vitro overexpression and knockdown treatments using miRNA mimic and 
inhibitor respectively.  
4.5.2 Agonist and antagonist 
5 treatment groups were prepared for this experiment- no treatment, lipid (lipofectamine), 
siNT1 (non-target inhibitor), mimic for miR-215-5p and inhibitor for miR-215-5p (siRNA). 
For this miRIDIAN miRNA miR-215-5p-mimic (catalogue# C-300570-05-0002) and 
miRIDIAN miRNA miR-215-5p-hairpin inhibitor (catalogue# IH-300570-07-0002), both from 
Dharmacon™ was used.  
4.5.3 Transfection of cells  
The procedure was started off with the preparation of cells on day 0. The whole procedure of 
transfection was done by a colleague at CSIRO-AAHL. Chicken DF1 (embryonic fibroblast) 
cells were seeded on the day before transfection in 96-well plate format at 8 x 103 cells/well. 
The cells were cultured in DMEM commercially available from Life Technologies. It also 
contained 10% foetal calf serum, 1mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml 
penicillin. The cells were incubated at 37 ̊C in a humid incubator with 5% CO2. 
Run mode Standard   
Sample volume 20μL   
Thermal cycling 
conditions:     
Step 
Enzyme Activation  PCR   
HOLD 
CYCLE (40 
cycles)   
Denature Anneal/Extend 
Temperature 95˚C 95˚C 60˚C 
Time 10 minutes 15 seconds 60 seconds 
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For transfection, the 40nM of mimic and inhibitor was used, using 0.25 µL lipofectamine2000 
reagent/well. This lipofectamine was also solely used for lipid treatment by diluting 0.25 µL 
LF2000 in 25 µL OptiMEM/well. The treatments were performed in a group of 3 technical 
replicates. The cells were allowed to grow confluent (approximately 1 x 106 cells/well) for 48 
hours. The uninfected cells were harvested post 48 hours of transfection for validation of 
transfection by qPCR of lysates. The rest were equally divided for infection- half were infected 
with H1N1 and the rest with H3N2 virus. The infected cells were harvested 72 hours post 
transfection (24 hours post infection) for validation. 
4.5.4 qRT-PCR 
4.5.4.1 RNA extraction 
The DF1 cells were flash frozen in -80˚C freezer and the infected cells were Qiazol inactivated 
before freezing. Tubes were labelled for 3 technical replicates each of no treatment, lipid, 
siNT1, mimic and inhibitor treated of mock ((48 hrs post transfection), H1N1 and H3N2 
infected DF1 cells (72 hrs post transfection and 24 hrs post infection).  
RNA was extracted using Qiagen miRNEasy micro kit and as per the protocol in section 4.4.2. 
The steps involving tissue lysis were excluded for this. The infected cells were first neutralised 
using Qiazol and then was handed over for the rest of the protocol to be performed. 
4.5.4.2 Selection of housekeeping gene 
GAPDH gene was used as the housekeeping gene for SYBR Green Real Time-qPCR as its 
expression is not affected by the viral replication in the cells (Eisenberg and Levanon, 2013).  
For TaqMan Real Time-qPCR for validating miR-215-5p expression, miR-454-3p was selected 
as a putative housekeeping miRNA. This selection was done based on manual normalisation 
of the NGS data for expression of miRNAs. Firstly, the raw read counts were converted into 
counts per million (CPM) mapped reads. With this, the coefficient of variation (CoV) (standard 
deviation/mean) for each miRNA was calculated. The miRNA candidate with lowest CoV was 
sorted. It was confirmed that it was abundantly expressed, and it was unresponsive to treatment 
i.e. it wasn’t was differentially expressed in mock or H1N1 and H3N2 infection. Also, it was 
confirmed that it was homologous to human miR-454-3p and a TaqMan assay was 
commercially available.  
4.5.4.3 cDNA synthesis 
TaqMan® MicroRNA Reverse Transcription kit, Applied Biosystem (catalogue# 4366596) 
was used for cDNA synthesis and TaqMan RT miR-215-5p (catalogue# 4427975) primer was 
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used. The protocol has been discussed in section 4.4.2.1. The RNA from H1N1 and H3N2 DF1 
cells were taken. Only the reagent per reaction was differed for this which is shown in table 
4.7. 







cDNA for SYBR Green Real Time-qPCR was synthesised using Superscript III First Strand 
Synthesis Supermix (catalogue# 18080-400). The primers used were (WHO, 2009): 






The components were mixed thoroughly and centrifuged briefly before use. The thermocycler 
was preheated to 65˚C. in labelled 0.2mL PCR tubes, 1 µL random hexamers, 1 µL of annealing 
buffer, 5 µL of NF water and 1 µL of RNA was added. These tubes were kept on ice. These 
were incubated for 5 minutes in the preheated thermocycler and then placed on ice for a minute. 
Reagent Per rxn 
100mM dNTPs 0.12 
Reverse Transcriptase 0.8 
RT Buffer 1.2 
Rnase Inhibitor 0.152 
NF Water 3.328 





To these tubes, 2 µL of enzyme mix (Superscript III) and 10 µL of 2X reaction mix was 
pipetted. These were mixed by brief vortexing and spinning before putting into thermocycler. 







4.5.4.4 SYBR Green qRT-PCR 
SYBR Green MasterMix (catalogue# 4309155) was used to perform RT-qPCR. First, the 
cDNA of each sample obtained from the previous step was diluted in 1:5 so that the final 
volume is enough to put 5 µL per well for 2 targets. Following table 4.10 the reagents were 
added into 96-well plate. The plate was sealed properly and was centrifuged at 3000g for 5 
minutes at RT. The set up for PCR had 2 phases- cycling stage and melt curve. The cycling 
stage consisted of 40 cycles of PCR with 95˚Cfor 10’, 95˚C for 15’’ and 60˚C for 1’. The 
melt curve consisted of 95˚C for 15’’, 60˚C for 1’ and 95˚C for another 15’’. 








(min) Temperature (˚C) 
Hold 10 25 
Hold 50 50 
Hold 5 85 
Hold ∞ 4 
Reagent Per reaction (μL) 
SYBR Green 10 




4.5.4.5 TaqMan qRT-PCR 
This was done to check the effect of 5 different treatments in H1N1 and H3N2 infected DF1 
cells on expression of miR-215-5p. the protocol has been discussed in section 4.4.2.2. Only the 
reagent per reaction was differed for this which is shown in table 4.11. 








4.5.5 Data analysis 
The data from qRT-PCR was first normalised manually using a method that is numerically 




3.32) where (CT-40)/-3.32 gives us an approximation of the log10 copies of the target genes. -
3.32 is the slope of the linear equation of the theoretical standard curve obtained and 40 is the 
number of cycles it has been amplified for. It was standardised with the copy number of the 
housekeeping gene and was scaled using means and standard deviation. 
Further, for statistical analysis, two-tailed, unpaired t-test was done to check the significance 






Reagent Per rxn 
TaqMan Assay (20X) 1 
Fast Universal qPCR Mastermix 10 





5.  Results 
5.1 Overview of miRNAs 
A total of 20.49 Gb of data was yielded through NGS of which 202,887,004 reads were 
generated (table 5.1). Out of this, 27,189,341 reads could be mapped to the chicken genome. 
These were obtained from H1N1 and H3N2 infected as well as non-infected chicken CAM 
tissues. The reads sequences matched to 894 microRNAs which corresponded to the chicken 
miRBase21 database. This database contains 1232 mature and 882 hairpin miRNA sequences. 
Of the sequenced miRNAs, 10 belong to gga-let-7 family and the rest to 679 different miRNA 
families.   
Table 5.1 Data generated in NGS 
 






MIR1 15,480,380 2795832.26 12,684,548 
MIR2 16,474,079 1321436.5 15,152,643 
MIR3 12,781,267 1388755.13 11,392,512 
MIR4 11,866,476 2401495.01 9,464,981 
MIR5 14,453,627 1201380.49 13,252,247 
H1N1 
MIR6 13,566,388 1750671.54 11,815,716 
MIR7 12,231,948 2592433.46 9,639,515 
MIR8 12,741,200 1265048.15 11,476,152 
MIR9 13,703,138 2658666.49 11,044,472 
MIR10 12,921,845 1661849.91 11,259,995 
H3N2 
MIR11 13,095,822 2379304.16 10,716,518 
MIR12 13,261,624 2582543.22 10,679,081 
MIR13 13,597,375 2432702.74 11,164,672 
MIR14 12,147,833 229959.55 11,917,873 
MIR15 14,564,002 527262 14,036,740 




Fig 5. 1 Various expressed miRNAs in (H1N1 and H3N2) infected and non-infected CAM 
of chicken. The log10 scaling of cumulative number of expressed reads of mapped miRNAs in 
infected and non-infected chicken CAMs. The orange dots represent the miRNAs which were 
later obtained as significant hits from DESeq2. 
Fig 5.1 and 5.2 represent the expression levels of different mapped miRNAs. These were drawn 
from the raw counts obtained from NGS. In fig 5.1, all miRNAs are shown, sorted by their 
abundance. Fig 5.2 highlights the top 20 abundant miRNAs in infected as well as non-infected 
CAMs. 
As can be seen in fig 5.1, the highest value corresponds to 6.6 which when converted to the 
number of reads, gives us an estimated value of 4,056,577. This is highlighted in fig 5.2 and 
gga-miR-126-3p is the most abundant of all of them. The next most abundant is gga-miR-143-
3p whose expression is almost half of the previous miRNA. The lowermost values in fig 5.1 
are the miRNAs where only one read was detected during NGS.  



































Fig 5. 2 Expression of the top 20 most abundant miRNAs in the CAM 
5.2 Characterisation of the miRNAs 
To differentiate the mapped miRNAs from the viral miRNAs and short reads from viral RNA 
fragments, BLAST+ was performed with chicken hairpin miRNAs as query against influenza 
A viral genome. This provided with local alignment of the queries. A list of BLAST result was 
obtained which returned 220 hits of which the top 2 has been shown in table 5.2. It can be 
observed the top hit of BLAST of hairpin miRNA against influenza A viral genome was gga-
mir-1630 against NC_007368.1. This miRNA was 75% identical to cRNA of segment 6 of 
Influenza A virus (A/New York/392/2004(H3N2)).  
Table 5. 2 Top 2 hits from BLAST+ 
 



























Expression levels of top 20 abundant miRNAs
Total raw counts
qseqid sseqid qlen slen length pident mismatch gapopen evalue qframe sframe
gga-mir-1630 ref|NC_007368.1| 57 1467 48 75 11 1 0.002 1 1
gga-mir-1684a ref|NC_004911.1| 102 2328 80 66.25 23 4 0.004 1 -1
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To support this result, Clone Manager was used to see the multiple sequence alignment between 
the viral genome, hairpin miRNA and mature miRNA obtained from NGS. The scoring matrix 
was linear and penalty scores for mismatch was 2, open gap 4 and extended gap 1. When mature 
miR-1630 and hairpin mir-1630 were aligned against each other, they showed matched 
sequences. But, cRNA are synthetic transcripts made in vitro (King, 1976). They don’t occur 
naturally and hence, the miRNAs mapped weren’t viral miRNAs. 
Table 5. 3 Global alignment for gga-mir-1630, miR-1630 and viral genome. The red box 






Sequence Start End Match Non-match %Match
NC_007368.1 1 1467
gga-mir-1630 1 57 52 1415 3
gga-miR-1630 1 22 21 1446 1
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Fig 5. 3 Volcano plots of significant hits of DESeq2. Representation of significant hits of (A) 
Mock vs H1N1, (B) Mock vs H3N2  x-axis signifies log2 fold change and y-axis signifies -
log10 P. NS stands for non-significant, P for significance value and FC for fold change. The cut 










Table 5. 4 Significant hits of DESeq2 along with log2 fold change 
 
A total of 894 miRNAs matched with the already available miRNA sequences in miRbase. 
After the optimisation of the raw counts reads of NGS data, 465 miRNAs were found to have 
enough expression levels to perform differential expression analysis. The raw counts were 
normalised using DESeq2 which is based on a null hypothesis of logarithmic fold change                                                    
(Love et al., 2014). It was observed that the normalisation of the counts initially led to highlight 
4 differentially expressed miRNAs in mock vs H1N1 testing, that were considered for further 
analysis when the significance threshold was set at 0.05. These were miR-215-5p, miR-429-
5p, miR-449a andmiR-1397-5p. Relaxing the stringency of the significance threshold yielded 
a new miRNA in the same test group- miR-194.  In mock and H1N1 infected groups, chicken 
miR-194, miR-215-5p, miR-449a and miR-1397-5p were found to be upregulated and miR-
429-5p to be downregulated. Likewise, for mock vs H3N2, 15 miRNAs were found to be 
differentially expressed (fig 5.3 and table 5.4). Fig 5.4 summarises the common differentially 
expressed miRNAs between the 3 sample contrasts- mock, H1N1 and H3N2 infected. Chicken 
miRNA log2FoldChange pvalue padj
Mock vs H1N1 gga-miR-1397-5p 1.05688261 0.000206 0.03079
gga-miR-194 1.049442233 0.000765 0.070346
gga-miR-215-5p 1.348528131 2.16E-07 9.92E-05
gga-miR-429-5p -0.579479853 0.000268 0.03079
gga-miR-449a 1.001344123 0.000234 0.03079
Mock vs H3N2 gga-miR-107-3p -0.299387211 0.003208 0.098671
gga-miR-1329-3p -0.784520495 0.003426 0.098671
gga-miR-138-5p -0.869406432 0.002606 0.098299
gga-miR-1677-5p 0.956192778 0.00112 0.051168
gga-miR-191-3p 0.924933203 0.000517 0.03852
gga-miR-194 1.021696733 0.001225 0.051168
gga-miR-206 1.103169148 0.001233 0.051168
gga-miR-215-5p 1.415579149 8.20E-08 3.40E-05
gga-miR-222b-5p 1.016354995 0.003633 0.098671
gga-miR-26a-2-5p -0.267808817 0.000367 0.038073
gga-miR-26a-5p -0.267808817 0.000367 0.038073
gga-miR-34b-5p -0.967471328 0.003493 0.098671
gga-miR-425-3p 0.758464103 0.000557 0.03852
gga-miR-429-5p -0.860948942 2.12E-07 4.40E-05
gga-miR-449a 0.928938924 0.000911 0.051168
gga-miR-449c-5p 0.83648693 0.003804 0.098671
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miR-194, miR-215-5p, miR-449a and miR-429-5p were found to be differentially regulated in 
infected and non-infected samples. 
The normalised miRNAs were illustrated in fig 5.5 (A) in hierarchal clustering based heatmap.  
There is no distinct pattern of expression of miRNAs in fig 5.3 (A) but when the expression 
was represented for the significant hits obtained 5 miRNAs (fig 5.5 (B)), a distinction of 
expression can be observed between the non-infected and infected ones. The miRNA 
expression of MIR 14 and 15 doesn’t match with the rest of the samples of the same group. 
These seems to be outliers of the sample group. As can be noted from fig 5.5 (B), miR-194, 
miR-215-5p, miR-449a and miR-1397-5p were found to have an increased expression in 
infected samples which was marked by the green colour in samples MIR6-13 while in miR-
429, decrease in expression levels was observed that was clearly distinguished by the red 
shades in samples MIR6-13. Thus, H1N1 and H3N2 viral infection imparted similar kind of 







Fig 5. 4 Venn diagram denotes commonly expressed miRNAs sorted from NGS data 









Fig 5. 5 Heatmap showing expression levels of regulated miRNAs. MIR1-5 represents 
mock, MIR6-10 represents H1N1 infected and MIR11-15 represents H3N2 infected. Red 
indicates downregulation and green indicates upregulation. Rows represent expressed miRNAs 
and columns represent the samples. The dendrogram on the left-hand side is the result of 
clustering of miRNAs (A) represents all the miRNAs whereas (B) depicts the miRNAs that 
were found to be top hits of DESeq2. Note: (B) is a subset of (A). 
 
5.4 Target prediction and their potential role in biological processes 
At this stage, the differentially expressed miRNAs were found and it was important to explore 
the probable targets these miRNAs can bind to and hence, regulate their expression either 
directly or indirectly and thereby, inhibiting or stimulating them. It also became imperative to 
probe the potential roles of the target genes in various biological processes. Using miRanda, 
22, 684, 159 and 105 targets were predicted for miR-215-5p, miR-449a, miR-1397-5p and 
miR-429-5p respectively. miR-449a seemed to have a larger repertoire of target genes that 
implied that it regulates gene expression It was realised that genes MDFIC and MBTD1 were 
the common target genes for miR-1397-5p, miR-429-5p and miR-449a (fig 5.6). A common 
binding site tends to elevate the efficiency of miRNA-based regulation of gene expression. 
Other common target genes are illustrated in fig 5.6. These targets were enriched using DAVID 
Resource Database and led to formation of annotation cluster. miR-215-5p had 1, miR-429-5p 
had 15, miR-449a had 112 and miR-1397-5p had 24 annotation clusters. The enrichment score 
signifies the relative importance of that gene group in the gene list.   
Target enrichment led to KEGG pathway (table 5.5) and GO (table 5.6) analysis. From the 
annotation clustering, KEGG pathways were sorted for those genes involved in immune-based 
processes and viral pathology. Since enrichment is a technique that often generates false 
positives, it is a justified and common approach to filter out hits that make no sense in the 
context of the study. It is known that any findings made in this way requires further validation 
before drawing any major conclusions. It was found that 14 target genes (P < 0.1) were 
involved in hepatitis B, 16 in viral carcinogenesis and 10 in measles virus infection. All the 
target genes belong to miR-449a. When GO analysis was applied, 15 genes (P < 0.5) were 
directly involved with immune-related biological processes. Some of the genes were involved 
in viral replication which points out their role in viral gene regulation. The genes were target 
for miR-449a and miR-1397-5p. The larger number of genes involved in such significant roles 
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can be credited to the large pool of target genes they have. It was evident by this analysis that 
their possible roles were in host-immune response and viral growth. It was quite surprising 
from table 5.5 that the probable target genes are involved in influenza A pathway. Further study 
is required to understand this result. 
 
 
Fig 5. 6 Venn diagram showing the number of target genes predicted. The overlapping of 


























hsa04612:Antigen processing and 
presentation 5 0.361474 0.8854555
GO term Count P-value
Corrected P-
value
GO:0042110~T cell activation 8 0.0011257 0.528745905
GO:0039702~viral budding via host ESCRT 
complex 3 0.1775964 0.993731603
GO:0031295~T cell costimulation 7 0.0544154 0.999262041
GO:0006281~DNA repair 9 0.5768114 0.997215187
GO:0046718~viral entry into host cell 6 0.1464773 0.989438434
GO:0050434~positive regulation of viral 




5.5 Validation of miRNA differential expression in CAM 
In order to determine the biological significance of DE miRNAs, 2 miRNAs were selected for 
validation. The promising candidates selected were - miR-215-5p (upregulated) and miR-429-
5p (downregulated). SET 1 (section 5.4.2) samples were used to validate the miRNAs.  
From fig 5.7 it can be studied that miR-429-5p in infected samples had higher CT mean values 
as compared to that of the uninfected. CT value is inversely proportional to its expression which 
means that lower CT value, higher will be its expression. In this case, it indicated that had lower 
expression levels in infected groups. Also, the values were highly significant as was observed 






   












Fig 5. 7  Validation of miR-429-5p in SET 1 samples. (A) x-axis denotes the various 
treatment groups and y-axis refers to CT  (threshold cycle) mean. ** represents the significance 
value (P):  P < 0.01. The y-axis has been reversed to correspond with the level of expression. 
(B) represents unpaired, two-tailed t-test result. Df value indicates degree of freedom. The error 







Unpaired t test 
 
MOCK vs H1N1 
 
P value 0.043 
P value summary * 
Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? Two-tailed 
t, df t=2.403, df=8 
  
MOCK vs H3N2 
 
P value 0.0029 
P value summary ** 
Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? Two-tailed 




Fig 5.8 represents the expression of miR-215-5p in SET 1 samples. It was seen that CT value 
of mock is quite higher as compared to the infected groups. Though one of the sample’s (H1N1 
infected) CT value was in the range of mock, but the mean is lower than the mock. This 
suggested higher level of expression of miR-215-5p in the infected groups. The P value for 
both sets of tests indicated to be significant.  















Fig 5. 8 Validation of miR-215-5p in SET 1 samples. (A) x-axis denotes the various 
treatment groups and y-axis refers to CT  (threshold cycle) mean. Significance value (P): if P 
< 0.01, then ** and if P<0.05, then *. The y-axis has been reversed to correspond with the 
level of expression. (B) represents unpaired, two-tailed t-test result 
 
 
Unpaired t test 
 
MOCK vs H1N1 
 
P value 0.0021 
P value summary ** 
Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? Two-tailed 
t, df t=4.452, df=8 
  
MOCK vs H3N2 
 
P value 0.0056 
P value summary ** 
Significantly different (P < 0.05)? Yes 
One- or two-tailed P value? Two-tailed 































Fig 5. 9 Validation of miR-429-5p in SET 2 samples. x-axis denotes the various treatment 
groups and y-axis refers to CT  (threshold cycle) mean.  
 
Fig 5.9 and 5.10 represent the validation of miR-429-5p and miR-215-5p in samples of SET 2. 
These were the samples where viral growth wasn’t as high. This didn’t validate the miRNAs 
as what was seen while validating using SET 1 CAMs. The measurements weren’t significant 
as tested using t-test and great variation as can be seen through error bars.  
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Fig 5. 10 Validation of miR-215-5p in SET 2 samples. x-axis denotes the various treatment 
groups and y-axis refers to CT  (threshold cycle) mean. * means P < 0.05 
 
5.6 miRNA levels in different tissues 
It is known that protein coding gene expression may be different in various tissues, similarly 
miRNA expression also differs from tissue to tissue. In addition to studying the differential 
expression of miRNAs in different treatments, it is important to know the baseline level of 
expression in non-infected condition. To analyse this, expression of miR-429-5p and miR-215-
5p was studied in various non-infected adult chicken tissues (fig 5.11). Lower CT values means 
higher expression, so the tissue of interest must have minimum CT value. The tissues used in 
this experiment were: serum, spleen, lungs, brain and liver. Lungs have some similarities with 
the CAM being involved in exchange of gases and may have more immune cells and 
inflammatory properties than any other tissue type. The tissues included serum, non-immune 
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and immune types. It was noticed that the expression levels of miR-429-5p was highest in 
lungs, followed by liver. The levels could be distinguished from the non-immune tissues. For 
miR-215-5p, the CT values were not so eminently different in the 5 types of tissues though the 
CT mean was maximum in lungs and then shadowed by liver. 
Fig 5. 11 miRNA expression levels in serum, 2 immune (spleen and lungs) and 2 non-

























































































5.7 Overexpression and knockdown treatments 
                                 
 
Fig 5. 12 Expression of miR-454-3p and miR-215-5p in (A) uninfected and (B) infected 
DF1 cells 48 hours and 72 hours of post transfection respectively. This is a log scale 
representation. Infected labelled cells were inoculated with H1N1 and H3N2 with known 
viral titres after 48 hours of transfection and were harvested 24 hours later (24 hours post 




In vitro gain-of-function and loss-of function studies were done to investigate the impact of 
miRNA differential expression. This study was done to explore the role of miR-215-5p in the 
chicken DF1 cell line in response to influenza infection. DF1 cells were used instead of eggs 
because of its feasibility over the use of eggs. Since, a large number of samples were involved 
in this study, it was better to use DF1 cells than eggs on the basis of being cost-effective, less 
time consumption and low labour-intensive.  
The uninfected samples were analysed separately from the uninfected samples because of the 
different time of harvesting of cells. It would have been better to harvest all the cells at the 
same time so as to negate the time-variable factor. It was indicated by fig 5.12 (A) that the 
expression of miR-215-5p was very high when it was transfected with mimic as compared to 
the rest of the conditions. miR-454-3p expressed consistently in null, lipid and siNT1 
transfected cells but there was a slight decrease in its expression in mimic transfected. This 
might point out the inefficiency of miR-454-3p as a housekeeping gene. In fig 5.12 (B), miR-
215-5p was highly expressed in H1N1 and H3N2 infected cells in presence of mimic. As 
compared to this, it was expressed in lower copy number in other environments while miR-
454-3p was expressed consistently in all the conditions in both kind of infected cells. In 
addition to this, except in mimic treatment, miR-454-3p had elevated expression in all the 
treatment groups when compared with miR-215-5p. Another point of observation from this 
figure was the similarity in the expression of the test miRNA and the housekeeping gene in 
both H1N1 and H3N2 infection as could be expected. 
Fig 5.13 (A) and (B) represent graphs for fold change in expression of miR-215-5p when 
normalised against fold change in the absence of any treatments. In fig 5.13 (A), the fold change 
was highest in the presence of a mimic of miR-215-5p which was followed by the fold change 
in inhibitor. Fold change was the same in null, lipid and non-target small interfering RNA 
(siNT1). Lipid and non-targets treatments were the controls to check for their interference in 
expression. In infected cells, this was the same. Both H1N1 and H3N2 infected cells indicated 
same pattern of fold change with a slight increase in H1N1 infection when treated with mimic. 
This was significant when statistically analysed. 
These results didn’t provide any significant evidence of gain or loss-of function of gene in the 
presence of agonist and antagonist of miR-215-5p. But, further laboratory work was undertaken 





Fig 5. 13 miR-215-5p expression relative to no treatment (log scale) in (A) uninfected DF1 
cells (48 hours post transfection) and (B) infected DF1 cells (72 hours post transfection). 
x-axis is different treatments and y-axis is the relative expression of miR-215-5p per 1000 
copies of miR-454-3p standardised against the expression in null treatment. * indicates the 
range of P value from 0.01-0.05. 
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qRT-PCR was performed to measure viral RNA to check if viral replication was affected by 
any of the treatments. The analysis of SYBR Green RT-qPCR products was done and 
represented in fig 5.14 and 5.15. This was performed to check the effect of these treatments on 
the viral growth. Primers targeted for viral matrix protein (MP) 1 was used to represent the 
viral genome and GAPDH gene was used as a housekeeping gene. GAPDH was expressed in 
consistent amounts in both H1N1 and H3N2 infected cells. Also, the expression of MP1 gene 
was steady for H1N1 and H3N2 infection respectively. MP1 was expressed in lower 
concentration in H3N2 when compared with that in H1N1 infected cells. Though the copy 
number of each gene appeared to be constant for a particular infection for all the treatments, 
the fold change optimised against null treatment had a slightly differed pattern to show. The 
fold change was maximum for mimic and inhibitor transfected cells. It was also seen that except 




















































































































































































Fig 5. 14 Expression of viral genome and GAPDH gene. Cell lysates of differently treated 
infected DF1 cells were harvested at 72 hours of post transfection (24 hours post infection). 
This graph represents the number of copies of viral genome per 1000 copies of GAPDH gene 



























































Fig 5. 15 Expression of viral genome relative to no treatment. x-axis represents treatments 
whereas y-axis represents the relative expression of viral genome per 1000 copies of GAPDH 






Vaccines are an integral part of the fight against influenza, which affects a huge population of 
humans and animals around the globe. The conventional method of production of influenza 
vaccines uses embryonated chicken eggs (Hannoun et al., 2004). CAM has been found to be 
the main site of viral replication in eggs. Because of this, CAM has become a focal part of 
many studies. It is recognised to have a much larger role rather than just being the site of 
replication, and is believed to mediate a host immune response against the influenza virus 
(McDonald, 2017). Some studies aim to understand the molecular changes the virus brings 
about in eggs and others focus on the reciprocal. The former type of studies is being conducted 
to unravel the mysteries surrounding the host response in CAM to influenza infection. These 
host responses include molecular changes such as gene expression which may be regulated via 
different factors such as mRNA (coding RNA), miRNA (non-coding RNA) and other small 
interfering RNAs and proteins. The changes in the mRNA pool has already been explored and 
deeply studied. This has also thrown some light on the possible role of miRNAs during viral 
replication in CAM. This project aimed to explore further the question of the role of miRNAs 
in influenza infection and was the first study of miRNA in CAM during influenza infection 
with different strains. 
There has been a remarkable impact of miRNA expression on the understanding of molecular 
changes in gene regulation. They have been proven to be strongly linked with pathogen and 
host resistance mechanisms. There is evidence that miRNAs elicit host immune response 
against viral infections. This implies that for influenza infection, it might contribute to 
understanding those mechanisms which might increase the efficiency of viral vaccines 
generated in embryonated chicken eggs. Therefore, it is important to identify and characterise 
the critical differentially expressed miRNAs in the chicken immune response against influenza 
infection. This would also help differentiate the chicken miRNAs from the viral small RNAs, 
which are known to be expressed by some viruses. This study has successfully identified 
differentially expressed miRNAs in influenza infection,followed by positive validation of the 
2 most promising miRNAs- miR-215-5p and miR-429-5p. To establish a successful correlation 
between miR-215-5p and viral infection, more tests needed to be performed.  
For this study, the 2 strains of influenza A were: A/California/07/2009 H1N1 and A/Hong 
Kong/4801/2014 H3N2. As is evident from Fig 1.3, these were the major influenza A subtypes 
active during the seasonal influenza epidemic of 2017 in Australia. These have been used 
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recurrently in vaccine production. Hence, they formed the basis of the research work. In this 
study, Illumina Next Generation Sequencing was first used to identify all the expressed 
miRNAs in H1N1 and H3N2 infected as well as uninfected CAMs. This is a more recent and 
precise, high throughput sequencing (HTS) technique, and is more efficient than the traditional 
cloning technique previously used which was time-consuming and labour-intensive (Burnside 
et al., 2008). This sequencing approach is more powerful than other conventional technologies 
previously used in birds since it was able to detect as low as one read of miRNA (gga-miR-
6703-3p, gga-miR-216b (fig 5.1)). NGS was able to successfully reveal various miRNAs that 
were expressed during influenza infection. Of these, there was a fair chance of novel miRNAs 
discovery. 894 miRNAs were found to be expressed out of the 1232 chicken miRNAs present 
in miRbase 21 database. Of these, 465 miRNAs were  found to be sufficiently abundant to 
perform differential expression analysis, following normalization. The identification and 
characterisation of these miRNAs will play an important role in investigating the functions and 
regulatory mechanisms of miRNAs in the chicken eggs. Performing BLAST and multiple 
sequence alignment made it clear that the expressed miRNAs isolated from CAM tissues were 
not viral miRNAs and were expressed directly by the host as was illustrated by the identity 
percentage. The topmost hit was only 75% identical which is too low to consider it to be of 
viral origin. Also, when this was aligned with influenza A viral genome, the match was with 
cRNA, a synthetic RNA (King, 1976) which doesn’t occur naturally.      
The most abundant reads to be found in the miRNA pool was that of gga-miR-126-3p 
regardless of the sample group. It is an intragenic miRNA which is transcribed from the intron 
7 of epidermal growth factor-like domain 7 (EGFL7) (Fish et al., 2008) This is known to play 
important roles in many biological processes such as mitogen-activated protein kinase (MAPK) 
signaling (Chen and Zhou, 2011) and ischemia-induced angiogenesis (Kuhnert et al., 2008, 
Nicoli et al., 2010). It’s expression is induced by 2 transcription factors, E26 avian leukemia 
oncogene (Ets)-1 and Ets-2 (Harris et al., 2010). It negatively regulates erythropoiesis (Huang 
et al., 2011). The second most abundant miRNA was gga-miR-143-3p (fig 20) which had half 
the number of expressed reads in the miRNA pool as compared to miR-126-3p. This miRNA 
is associated with mechanisms of sexual dimorphism development (Warnefors et al., 2017).  
Thus, the miRNA pool which were expressed in CAMs from different sample groups had 
functional roles in a varied array of biological processes.  
Bioinformatics is an interdisciplinary subject and the tools for analysis have aided in 
conceptualising non-coding RNA-mediated regulatory networks incorporating inferences from 
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NGS (Wong, 2016). The tools used for data analysis included DESeq2 for normalisation and 
differential expression testing, and miRanda for target prediction. The DESeq2 method is based 
on negative binomial distribution and local regression to estimate the relationship between the 
mean and variance of each gene. The method is based on the hypothesis that most genes are 
not differentially expressed (DE) and that non-DE genes should therefore have similar read 
counts across samples, leading to the ratio 1 (Love et al., 2014). DESeq2 successfully revealed 
5 significant hits that were being differentially expressed when samples of different groups 
were compared (MOCK vs H1N1 infected and MOCK vs H3N2 infected). These were as 
follows (table 6.1): 
Table 6. 1 Significant hits from DESeq 
miRNA Log2 fold change Behaviour in infected samples 
gga-miR-194 >1 Upregulated 
gga -miR-215-5p >1 Upregulated 
gga -miR-449a >1 Upregulated 
gga -miR-1397-5p >1 Upregulated 
gga-miR-429-5p <1 Downregulated 
 
This was clearly demonstrated in the heatmap (fig 5.5 (B)) where the upregulated miRNAs 
were shown in green colour and downregulated in red colour in infected samples except MIR14 
and MIR15, which appear to be outliers. This exception might be either because of the 
contamination of samples MIR14 and 15, or by strain selection by eggs (Hardy et al., 1995) or 
a technical replicate error. In an independent study on Avian Pathogenic Escherichia coli 
(APEC), it was that found that 3 out of 5 DE miRNAs in influenza infection (fig 6.1) were also 
differentially regulated in APEC infection in chicken (Jia et al., 2017). This suggest that these 
miRNAs (miR-429, miR-215 and miR-194) may have a more general role in the host response 





Fig 6. 1 Commonly expressed miRNAs in APEC and influenza infection 
It is useful to predict miRNA function by predicting the genes they target and annotation of 
their biological functions. miRanda was used, which predicts target genes based on sequence 
complementarity using a position-weighted local alignment algorithm, free energies of RNA-
RNA duplexes and conservation of target sites in related genomes (Min and Yoon, 2010). 
These target genes were enriched using DAVID Resource Database. These clustered miRNAs 
based on their annotations and the enrichment score implies the significance level of that gene. 
Further, GO term and KEGG pathway analysis gave information about the biological functions 
they may be involved in. The immune-based functions were highlighted in GO term analysis 
and many of them were involved in viral replication machinery. In KEGG pathway also, the 
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target genes were a part of various viral pathogenesis as well as immune based functions. Most 
of the genes relate to miR-449a and miR-1397-5p.  This indicated that DE miRNAs might be 
involved in direct or indirect regulation of immune based responses. 
Following analysis of the NGS data, putative DE miRNAs needed to be validated in the 3 
sample groups. 2 miRNAs, which seemed to be the most promising candidates were chosen for 
validation by RT-qPCR: gga-miR-215-5p for upregulation and gga-miR-429-5p for 
downregulation. As was seen in Fig. 5.7, the CT value of gga-miR-429-5p in infected cells were 
quite higher when compared with the mock. This implied that they were downregulated in 
infected samples contrast to the mock sample group. In Fig. 5.8, the mock had a higher CT 
value as compared to the infected samples which indicated the upregulation of gga-miR-215-
5p. These were performed on the samples that had good viral growth levels. When this study 
was repeated to replicate in additional samples in which the viral levels were much lower, the 
results could not be replicated. This pointed out the anomaly of the host immune response being 
responsive and regulated by these miRNAs only in high viral titres. It seemed that at a certain 
degree of viral growth the miRNAs were differentially expressed as the miRNAs were 
successfully validated in CAMs which had good viral growth. It may also depend on the 
genetics of the eggs which influences its likelihood to get infected. The native expression of 
these 2 miRNAs were studied in chicken non-infected tissues which included serum, 2 non-
immune tissues- brain and liver and 2 immune tissues- lungs and spleen. gga-miR-429-5p was 
highly expressed in lungs, followed by liver. It was not consistent with the other immune tissue; 
the spleen. gga-miR-215-5p did not show tissue specificity, although it seemed to be expressed 
in lungs and liver in the lowest concentration. By looking at the average, we could say that this 
was expressed in lowest quantities in liver. Further study on lungs could provide a better 
understanding of the effect of these miRNAs in immune associated cells. 
After the DE miRNAs were successfully validated, a functional study was designed to study 
the effects of gain- and loss-of function. For this, miR-215-5p was chosen. The reason for this 
selection was that miR-429-5p is not found in human whereas miR-215-5p has a homologue 
in human. As this would be performed in chicken DF1 cells and the agonist and antagonist 
reagents are commercially available only for humans, a miRNA had to be selected which is 
present in both humans and chickens. miR-215-5p has been associated with tumour growth. It 
was found that miR-215-5p is downregulated in colorectal tumour tissue in which promising 
tumour-suppressive features were observed (Faltejskova et al., 2012). It can reduce 
proliferation, clonogenicity and migration of colorectal cancer cells and lead to cell cycle arrest. 
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It has also been shown to act as an effector as well as regulator of p53 (Braun et al., 2008). It’s 
targets are denticleless protein homolog (Song et al., 2010) and thymidine synthase (Boni et 
al., 2010).   
DF1 cells were selected for this study as they relate to chickens, eggs, CAM and vaccine 
production. Analysis of infected and uninfected cells was carried out separately as the 
transfection period and the point of harvest is different. Uninfected cells were harvested 48 
hours post transfection whereas infected cells were harvested 72 hours post-transfection (24 
hours post-infection). In the presence of mimic, the detection of miR-215-5p was high which 
might imply there had been a gain-of-function. Unfortunately, this was not matched by the 
knock-down experiment, as there was no noticeable change detected. An experiment was 
performed to study the effects of these treatments on viral growth, using SYBR Green RT-
qPCR. No effect on the expression of viral encoded-MP1 was observed in either H1N1 and 
H3N2 infected cells. This suggested that neither the agonist or antagonist had any effect on 
viral growth. When the readings were normalised against the ‘null treatment’ this created 
another opinion, however, as the treatments did appear to differentially affect the growth of the 
two viruses, as suggested in fig 5.15. For H1N1 viral growth, it appeared to show a small 
increase in the presence of both mimic and inhibitor. This might be because of the difference 
in adaptability of virus in the particular environment (Gambaryan et al., 1999). Other reasons 
for these unexpected results might be the difference in the cell lines. Also, it might be possible 
that the concentration of agonist and antagonists used weren’t sufficient to produce an effect. 
The validation of these miRNAs was done on CAM cells and it is known that different tissues 
serve various biological functions and which can have varied expression patterns of biological 
functions (Xu et al., 2006).  
Statistical analysis of the expression level of miRNAs in CAM showed some findings to be 
significant though some of them did not reach significance. This can be attributed to the small 
sample size. True differences might be missed by the tests as that cannot identify minor 
differences in small sample size. This might also elevate false positives. Future studies should 
include larger sample size so that the statistical tests will be able to pick up on the minor 
differences. Another important issue for detection of small numbers of DE miRNAs might be 
the low number of mapped reads; the small size of miRNA being one of the reasons for this.     
Analysis of NGS data highlighted 5 differentially expressed miRNAs. The range of DE 
miRNAs could have been broadened with less stringent criteria during the analysis. 
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Furthermore, more studies needed to be conducted to characterise the miRNA targets. These 
could have helped provide better understanding of the interaction between miRNAs and their 
target mRNA. We successfully validated 2 miRNAs. This validation study could have been 
performed for all the DE miRNAs. Also, during validation, the time of performing qRT-PCR 
was different for both the miRNAs. To minimise variations and error, all the samples of a 
particular set should be done at the same time and also wherever possible, on the smallest 
number of PCR plates. Housekeeping genes need to be used to measure the expression as part 
of the validation process. For future functional studies, the protocol needs to be modified in 
such a way so that the time of harvesting of cells is same for each group. Further research needs 
to be done before changing the cell line for functional studies. If time would have permitted, 
TCID50 could have been performed to confirm the effect of treatments on viral growth.  Last 
but not the least, some of the target genes could be validated to better understand the gene 
regulation network during influenza infection. 
Future studies could be performed to better understand the miRNA regulation in CAMs. The 
remaining 3 miRNAs could be validated along with identifying more differentially expressed 
miRNAs along with functional studies. Their predicted target genes could be validated to have 
a clearer understanding about their regulatory networks. A dose response study could be 
performed to validate the concentration of agonists and antagonists to produce an effect. 
TCID50 could be performed to investigate the effect of these treatments on viral growth. Also, 
more tissues could be included in the sample repertoire to investigate the presence of DE 
miRNAs. More studies need to be performed to understand their role in immune based 





In conclusion, the first characterization of CAM miRNA expression profile of the chicken in 
response to influenza A infection was performed. A total of 5 different expressed miRNAs 
were identified. Probable target genes were also predicted. When target enrichment was 
performed, their involvement in various biological functional roles were explored; some of 
which included immune based responses as well as viral pathology-based responses. The hits 
from DESeq2 were highly significant. Furthermore, the upregulating of miR-215-5p and 
downregulating of miR-429-5p were successfully validated in CAMs with high virus growth. 
Unfortunately, the CAMs with lower viral growth did not support this observation. In addition 
to this, these 2 miRNAs were found to be expressed in 5 tissues- serum, lungs, spleen, liver 
and brain. For the functional studies which were performed to investigate the impact of miRNA 
differential expression on viral growth, no significant changes were noticed. Also, the presence 
of an antagonist was unable to knock down miR-215-5p. These findings are the beginning of a 
process of understanding of the miRNA-driven gene regulation of the host immune response 
as well as viral growth with a long-term goal of dealing with the global crisis of influenza 
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